Within the Trend of Import Substitution
In the next year and a half, by 2018, 90% of drugs, included into the Vital and Essential Drugs List will be manufactured in Russia. The task was set by the Russian President this May for pharma industry.
Nine Russian drugs, replacing imported drugs in the Russian pharma market, were approved in H1 this year. Now full cycle production of import substituting drug from the VED list should be organized. It will be facilitated by a system of public support and subsiding both of their development and research (clinical and preclinical).
Recently amendments were made into the federal law on contract system to facilitate conclusion and implementation of special investment contracts and offset deals, to provide opportunities for local production. International companies are already investigating the potential for cooperation on the corresponding investment contracts.
The policy of import substitution helps implement state-of-art technologies and improvement of quality of Russian drugs. It provides an opportunity for our pharma manufacturers to expand the market, and gives our manufacturers from EEU potential opportunity of unrestricted supply to Russia of their high quality products.